1. Home
  2. WIA vs PLX Comparison

WIA vs PLX Comparison

Compare WIA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Inflation-Linked Income Fund

WIA

Western Asset Inflation-Linked Income Fund

HOLD

Current Price

$8.08

Market Cap

191.5M

Sector

Finance

ML Signal

HOLD

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

HOLD

Current Price

$2.19

Market Cap

174.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WIA
PLX
Founded
2003
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
191.5M
174.0M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
WIA
PLX
Price
$8.08
$2.19
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
49.5K
1.0M
Earning Date
01-01-0001
03-18-2026
Dividend Yield
12.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$52,744,000.00
Revenue This Year
N/A
$37.52
Revenue Next Year
N/A
$1.25
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.95
$1.34
52 Week High
$8.54
$3.19

Technical Indicators

Market Signals
Indicator
WIA
PLX
Relative Strength Index (RSI) 40.62 37.78
Support Level N/A $2.03
Resistance Level $8.31 $2.45
Average True Range (ATR) 0.06 0.12
MACD -0.00 -0.05
Stochastic Oscillator 45.83 15.17

Price Performance

Historical Comparison
WIA
PLX

About WIA Western Asset Inflation-Linked Income Fund

Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Share on Social Networks: